

Agilent announces global distribution agreement with Proscia

March 10, 2023—[Agilent Technologies](#) announced a multiyear distribution agreement with [Proscia](#) to offer a comprehensive digital diagnostic pathology system, combining Agilent's pathology staining solutions with Proscia's Concentriq Dx enterprise pathology platform.

"We are excited to partner with Proscia, a trailblazer in digital pathology, to deliver an open, scalable, and flexible digital pathology workflow with enhanced capabilities," Lou Welebob, vice president and general manager of Agilent's pathology division, Diagnostics and Genomics Group, said in a press statement. "This distribution agreement of Proscia's technology to Agilent's pathology customers demonstrates our continued commitment to providing pathologists with solutions to streamline and leverage the results of their image analysis, resulting in improved patient outcomes."

Concentriq Dx is CE marked under in vitro diagnostic regulation and is available for primary diagnosis in the United States during the COVID-19 public health emergency.